You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • THU0306 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of The BCL-2 Inhibitor Venetoclax (ABT-199) in A Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus

Citation Tools

Article menu
Download PDFPDF
Poster Presentations
SLE, Sjögren's and APS - treatment
THU0306 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of The BCL-2 Inhibitor Venetoclax (ABT-199) in A Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Lu P, Fleischmann R, Curtis C, et al
THU0306 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of The BCL-2 Inhibitor Venetoclax (ABT-199) in A Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus
Annals of the Rheumatic Diseases 2016;75:298.